Key Points

  • Genetically heterogeneous BC progenitors demonstrate molecular convergence on PRC1- and PRC2-regulated pathways.

  • A model of PRC-driven reprogramming identifies novel BC combination therapies, tumor suppressor genes, and biomarkers for transformation.

Abstract

Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterations that confer stemness features to progenitor populations and resistance to BCR-ABL1 tyrosine kinase inhibitors. Comprehensive models of BC transformation have proved elusive because of the rarity and genetic heterogeneity of BC, but are important for developing biomarkers predicting BC progression and effective therapies. To better understand BC, we performed an integrated multiomics analysis of 74 CP and BC samples using whole-genome and exome sequencing, transcriptome and methylome profiling, and chromatin immunoprecipitation followed by high-throughput sequencing. Employing pathway-based analysis, we found the BC genome was significantly enriched for mutations affecting components of the polycomb repressive complex (PRC) pathway. While transcriptomically, BC progenitors were enriched and depleted for PRC1- and PRC2-related gene sets respectively. By integrating our data sets, we determined that BC progenitors undergo PRC-driven epigenetic reprogramming toward a convergent transcriptomic state. Specifically, PRC2 directs BC DNA hypermethylation, which in turn silences key genes involved in myeloid differentiation and tumor suppressor function via so-called epigenetic switching, whereas PRC1 represses an overlapping and distinct set of genes, including novel BC tumor suppressors. On the basis of these observations, we developed an integrated model of BC that facilitated the identification of combinatorial therapies capable of reversing BC reprogramming (decitabine+PRC1 inhibitors), novel PRC-silenced tumor suppressor genes (NR4A2), and gene expression signatures predictive of disease progression and drug resistance in CP.

REFERENCES

REFERENCES
1.
Sasaki
K
,
Strom
SS
,
O’Brien
S
, et al
.
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
.
Lancet Haematol
.
2015
;
2
(
5
):
e186
-
e193
.
2.
Bower
H
,
Björkholm
M
,
Dickman
PW
,
Höglund
M
,
Lambert
PC
,
Andersson
TM
.
Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population
.
J Clin Oncol
.
2016
;
34
(
24
):
2851
-
2857
.
3.
Perrotti
D
,
Jamieson
C
,
Goldman
J
,
Skorski
T
.
Chronic myeloid leukemia: mechanisms of blastic transformation
.
J Clin Invest
.
2010
;
120
(
7
):
2254
-
2264
.
4.
Branford
S
,
Wang
P
,
Yeung
DT
, et al
.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
.
Blood
.
2018
;
132
(
9
):
948
-
961
.
5.
McGranahan
N
,
Swanton
C
.
Clonal heterogeneity and tumor evolution: past, present, and the future
.
Cell
.
2017
;
168
(
4
):
613
-
628
.
6.
Konieczkowski
DJ
,
Johannessen
CM
,
Garraway
LA
.
A convergence-based framework for cancer drug resistance
.
Cancer Cell
.
2018
;
33
(
5
):
801
-
815
.
7.
Chen
H
,
He
X
.
The convergent cancer evolution toward a single cellular destination
.
Mol Biol Evol
.
2016
;
33
(
1
):
4
-
12
.
8.
Lytle
NK
,
Barber
AG
,
Reya
T
.
Stem cell fate in cancer growth, progression and therapy resistance
.
Nat Rev Cancer
.
2018
;
18
(
11
):
669
-
680
.
9.
Jamieson
CH
,
Ailles
LE
,
Dylla
SJ
, et al
.
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
.
N Engl J Med
.
2004
;
351
(
7
):
657
-
667
.
10.
Lim
S
,
Saw
TY
,
Zhang
M
, et al
.
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function
.
Proc Natl Acad Sci USA
.
2013
;
110
(
25
):
E2298
-
E2307
.
11.
Radich
JP
,
Dai
H
,
Mao
M
, et al
.
Gene expression changes associated with progression and response in chronic myeloid leukemia
.
Proc Natl Acad Sci USA
.
2006
;
103
(
8
):
2794
-
2799
.
12.
Zheng
C
,
Li
L
,
Haak
M
, et al
.
Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis
.
Leukemia
.
2006
;
20
(
6
):
1028
-
1034
.
13.
Koschmieder
S
,
Vetrie
D
.
Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
.
Semin Cancer Biol
.
2018
;
51
:
180
-
197
.
14.
Scott
MT
,
Korfi
K
,
Saffrey
P
, et al
.
Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition
.
Cancer Discov
.
2016
;
6
(
11
):
1248
-
1257
.
15.
Xie
H
,
Peng
C
,
Huang
J
, et al
.
Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2
.
Cancer Discov
.
2016
;
6
(
11
):
1237
-
1247
.
16.
Mohty
M
,
Yong
AS
,
Szydlo
RM
,
Apperley
JF
,
Melo
JV
.
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
.
Blood
.
2007
;
110
(
1
):
380
-
383
.
17.
Rizo
A
,
Horton
SJ
,
Olthof
S
, et al
.
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells
.
Blood
.
2010
;
116
(
22
):
4621
-
4630
.
18.
Sengupta
A
,
Ficker
AM
,
Dunn
SK
,
Madhu
M
,
Cancelas
JA
.
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells
.
Blood
.
2012
;
119
(
2
):
494
-
502
.
19.
Di Carlo
V
,
Mocavini
I
,
Di Croce
L
.
Polycomb complexes in normal and malignant hematopoiesis
.
J Cell Biol
.
2019
;
218
(
1
):
55
-
69
.
20.
Schuettengruber
B
,
Bourbon
HM
,
Di Croce
L
,
Cavalli
G
.
Genome regulation by polycomb and trithorax: 70 years and counting
.
Cell
.
2017
;
171
(
1
):
34
-
57
.
21.
Sparmann
A
,
van Lohuizen
M
.
Polycomb silencers control cell fate, development and cancer
.
Nat Rev Cancer
.
2006
;
6
(
11
):
846
-
856
.
22.
Koppens
M
,
van Lohuizen
M
.
Context-dependent actions of Polycomb repressors in cancer
.
Oncogene
.
2016
;
35
(
11
):
1341
-
1352
.
23.
Iwama
A
.
Polycomb repressive complexes in hematological malignancies
.
Blood
.
2017
;
130
(
1
):
23
-
29
.
24.
Basheer
F
,
Giotopoulos
G
,
Meduri
E
, et al
.
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
.
J Exp Med
.
2019
;
216
(
4
):
966
-
981
.
25.
Kim
KH
,
Roberts
CW
.
Targeting EZH2 in cancer
.
Nat Med
.
2016
;
22
(
2
):
128
-
134
.
26.
Alexandrov
LB
,
Nik-Zainal
S
,
Wedge
DC
, et al;
ICGC PedBrain
.
Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258]
.
Nature
.
2013
;
500
(
7463
):
415
-
421
.
27.
Gruber
TA
,
Chang
MS
,
Sposto
R
,
Müschen
M
.
Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia
.
Cancer Res
.
2010
;
70
(
19
):
7411
-
7420
.
28.
Feldhahn
N
,
Henke
N
,
Melchior
K
, et al
.
Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells
.
J Exp Med
.
2007
;
204
(
5
):
1157
-
1166
.
29.
Lawrence
MS
,
Stojanov
P
,
Polak
P
, et al
.
Mutational heterogeneity in cancer and the search for new cancer-associated genes
.
Nature
.
2013
;
499
(
7457
):
214
-
218
.
30.
Brady
N
,
Gaymes
TJ
,
Cheung
M
,
Mufti
GJ
,
Rassool
FV
.
Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins
.
Cancer Res
.
2003
;
63
(
8
):
1798
-
1805
.
31.
Gaymes
TJ
,
Mufti
GJ
,
Rassool
FV
.
Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer
.
Cancer Res
.
2002
;
62
(
10
):
2791
-
2797
.
32.
Mermel
CH
,
Schumacher
SE
,
Hill
B
,
Meyerson
ML
,
Beroukhim
R
,
Getz
G
.
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
.
Genome Biol
.
2011
;
12
(
4
):
R41
.
33.
Nacheva
EP
,
Brazma
D
,
Virgili
A
, et al
.
Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia
.
BMC Genomics
.
2010
;
11
(
1
):
41
.
34.
Belinky
F
,
Nativ
N
,
Stelzer
G
, et al
.
PathCards: multi-source consolidation of human biological pathways
.
Database (Oxford)
.
2015
;
2015
:
bav006
.
35.
Brookes
E
,
de Santiago
I
,
Hebenstreit
D
, et al
.
Polycomb associates genome-wide with a specific RNA polymerase II variant, and regulates metabolic genes in ESCs
.
Cell Stem Cell
.
2012
;
10
(
2
):
157
-
170
.
36.
Ben-Porath
I
,
Thomson
MW
,
Carey
VJ
, et al
.
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
.
Nat Genet
.
2008
;
40
(
5
):
499
-
507
.
37.
Eppert
K
,
Takenaka
K
,
Lechman
ER
, et al
.
Stem cell gene expression programs influence clinical outcome in human leukemia
.
Nat Med
.
2011
;
17
(
9
):
1086
-
1093
.
38.
Chen
T
,
Dent
SY
.
Chromatin modifiers and remodellers: regulators of cellular differentiation
.
Nat Rev Genet
.
2014
;
15
(
2
):
93
-
106
.
39.
Laugesen
A
,
Helin
K
.
Chromatin repressive complexes in stem cells, development, and cancer
.
Cell Stem Cell
.
2014
;
14
(
6
):
735
-
751
.
40.
Mills
AA
.
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins
.
Nat Rev Cancer
.
2010
;
10
(
10
):
669
-
682
.
41.
Sauvageau
M
,
Sauvageau
G
.
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer
.
Cell Stem Cell
.
2010
;
7
(
3
):
299
-
313
.
42.
Manning
G
,
Whyte
DB
,
Martinez
R
,
Hunter
T
,
Sudarsanam
S
.
The protein kinase complement of the human genome
.
Science
.
2002
;
298
(
5600
):
1912
-
1934
.
43.
Bai
Y
,
Lu
Z
,
Lin
Y
,
Sun
B
,
Wang
S
,
Wang
G
.
Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias
.
Oncol Res
.
2013
;
21
(
1
):
23
-
31
.
44.
Serrano
M
,
Gómez-Lahoz
E
,
DePinho
RA
,
Beach
D
,
Bar-Sagi
D
.
Inhibition of ras-induced proliferation and cellular transformation by p16INK4
.
Science
.
1995
;
267
(
5195
):
249
-
252
.
45.
Virely
C
,
Moulin
S
,
Cobaleda
C
, et al
.
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia
.
Leukemia
.
2010
;
24
(
6
):
1200
-
1204
.
46.
Dang
J
,
Wei
L
,
de Ridder
J
, et al
.
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia
.
Blood
.
2015
;
125
(
23
):
3609
-
3617
.
47.
Zhao
LJ
,
Wang
YY
,
Li
G
, et al
.
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia
.
Blood
.
2012
;
119
(
12
):
2873
-
2882
.
48.
Mullighan
CG
,
Miller
CB
,
Radtke
I
, et al
.
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
.
Nature
.
2008
;
453
(
7191
):
110
-
114
.
49.
Beer
PA
,
Knapp
DJ
,
Miller
PH
, et al
.
Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression
.
Blood
.
2015
;
125
(
3
):
504
-
515
.
50.
Yamamoto
K
,
Tsuzuki
S
,
Minami
Y
, et al
.
Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice
.
PLoS One
.
2013
;
8
(
9
):
e74864
.
51.
Hehlmann
R
.
How I treat CML blast crisis
.
Blood
.
2012
;
120
(
4
):
737
-
747
.
52.
Liberzon
A
,
Birger
C
,
Thorvaldsdóttir
H
,
Ghandi
M
,
Mesirov
JP
,
Tamayo
P
.
The Molecular Signatures Database (MSigDB) hallmark gene set collection
.
Cell Syst
.
2015
;
1
(
6
):
417
-
425
.
53.
Giustacchini
A
,
Thongjuea
S
,
Barkas
N
, et al
.
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
.
Nat Med
.
2017
;
23
(
6
):
692
-
702
.
54.
Ly
C
,
Arechiga
AF
,
Melo
JV
,
Walsh
CM
,
Ong
ST
.
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin
.
Cancer Res
.
2003
;
63
(
18
):
5716
-
5722
.
55.
Gentles
AJ
,
Plevritis
SK
,
Majeti
R
,
Alizadeh
AA
.
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
.
JAMA
.
2010
;
304
(
24
):
2706
-
2715
.
56.
Georgantas
RW
III
,
Tanadve
V
,
Malehorn
M
, et al
.
Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells
.
Cancer Res
.
2004
;
64
(
13
):
4434
-
4441
.
57.
Ernst
T
,
Chase
AJ
,
Score
J
, et al
.
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
.
Nat Genet
.
2010
;
42
(
8
):
722
-
726
.
58.
Nikoloski
G
,
Langemeijer
SM
,
Kuiper
RP
, et al
.
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
.
Nat Genet
.
2010
;
42
(
8
):
665
-
667
.
59.
Guglielmelli
P
,
Biamonte
F
,
Score
J
, et al
.
EZH2 mutational status predicts poor survival in myelofibrosis
.
Blood
.
2011
;
118
(
19
):
5227
-
5234
.
60.
Issa
JP
,
Gharibyan
V
,
Cortes
J
, et al
.
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
.
J Clin Oncol
.
2005
;
23
(
17
):
3948
-
3956
.
61.
Kantarjian
HM
,
O’Brien
S
,
Cortes
J
, et al
.
Results of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
.
Cancer
.
2003
;
98
(
3
):
522
-
528
.
62.
Kantarjian
HM
,
O’Brien
SM
,
Keating
M
, et al
.
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
.
Leukemia
.
1997
;
11
(
10
):
1617
-
1620
.
63.
Heller
G
,
Topakian
T
,
Altenberger
C
, et al
.
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
.
Leukemia
.
2016
;
30
(
9
):
1861
-
1868
.
64.
Asimakopoulos
FA
,
Shteper
PJ
,
Krichevsky
S
, et al
.
ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
.
Blood
.
1999
;
94
(
7
):
2452
-
2460
.
65.
Jelinek
J
,
Gharibyan
V
,
Estecio
MR
, et al
.
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
.
PLoS One
.
2011
;
6
(
7
):
e22110
.
66.
Baylin
SB
,
Jones
PA
.
A decade of exploring the cancer epigenome - biological and translational implications
.
Nat Rev Cancer
.
2011
;
11
(
10
):
726
-
734
.
67.
Maunakea
AK
,
Nagarajan
RP
,
Bilenky
M
, et al
.
Conserved role of intragenic DNA methylation in regulating alternative promoters
.
Nature
.
2010
;
466
(
7303
):
253
-
257
.
68.
Varley
KE
,
Gertz
J
,
Bowling
KM
, et al
.
Dynamic DNA methylation across diverse human cell lines and tissues
.
Genome Res
.
2013
;
23
(
3
):
555
-
567
.
69.
Tsai
HC
,
Li
H
,
Van Neste
L
, et al
.
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells
.
Cancer Cell
.
2012
;
21
(
3
):
430
-
446
.
70.
Lekstrom-Himes
JA
.
The role of C/EBP(epsilon) in the terminal stages of granulocyte differentiation
.
Stem Cells
.
2001
;
19
(
2
):
125
-
133
.
71.
Dawson
MI
,
Elstner
E
,
Kizaki
M
, et al
.
Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway
.
Blood
.
1994
;
84
(
2
):
446
-
452
.
72.
Batliner
J
,
Mancarelli
MM
,
Jenal
M
, et al
.
CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation
.
Mol Immunol
.
2011
;
48
(
4
):
714
-
719
.
73.
Nauseef
WM
,
Olsson
I
,
Arnljots
K
.
Biosynthesis and processing of myeloperoxidase--a marker for myeloid cell differentiation
.
Eur J Haematol
.
1988
;
40
(
2
):
97
-
110
.
74.
Thomas
LL
,
Haskell
MD
,
Sarmiento
EU
,
Bilimoria
Y
.
Distinguishing features of basophil and neutrophil activation by major basic protein
.
J Allergy Clin Immunol
.
1994
;
94
(
6 Pt 2
):
1171
-
1176
.
75.
Kang
T
,
Yi
J
,
Guo
A
, et al
.
Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils
.
J Biol Chem
.
2001
;
276
(
24
):
21960
-
21968
.
76.
Getting
SJ
,
Mahoney
DJ
,
Cao
T
, et al
.
The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner
.
J Biol Chem
.
2002
;
277
(
52
):
51068
-
51076
.
77.
Kahn
TG
,
Dorafshan
E
,
Schultheis
D
, et al
.
Interdependence of PRC1 and PRC2 for recruitment to Polycomb Response Elements
.
Nucleic Acids Res
.
2016
;
44
(
21
):
10132
-
10149
.
78.
Kreso
A
,
van Galen
P
,
Pedley
NM
, et al
.
Self-renewal as a therapeutic target in human colorectal cancer
.
Nat Med
.
2014
;
20
(
1
):
29
-
36
.
79.
McCabe
MT
,
Ott
HM
,
Ganji
G
, et al
.
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
.
Nature
.
2012
;
492
(
7427
):
108
-
112
.
80.
Yong
KJ
,
Basseres
DS
,
Welner
RS
, et al
.
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression
.
Sci Transl Med
.
2016
;
8
(
350
):
350ra104
.
81.
Gargiulo
G
,
Cesaroni
M
,
Serresi
M
, et al
.
In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis
.
Cancer Cell
.
2013
;
23
(
5
):
660
-
676
.
82.
Wiederschain
D
,
Chen
L
,
Johnson
B
, et al
.
Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
.
Mol Cell Biol
.
2007
;
27
(
13
):
4968
-
4979
.
83.
Bracken
AP
,
Dietrich
N
,
Pasini
D
,
Hansen
KH
,
Helin
K
.
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
.
Genes Dev
.
2006
;
20
(
9
):
1123
-
1136
.
84.
Ohm
JE
,
McGarvey
KM
,
Yu
X
, et al
.
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
.
Nat Genet
.
2007
;
39
(
2
):
237
-
242
.
85.
Widschwendter
M
,
Fiegl
H
,
Egle
D
, et al
.
Epigenetic stem cell signature in cancer
.
Nat Genet
.
2007
;
39
(
2
):
157
-
158
.
86.
Schlesinger
Y
,
Straussman
R
,
Keshet
I
, et al
.
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer
.
Nat Genet
.
2007
;
39
(
2
):
232
-
236
.
87.
Viré
E
,
Brenner
C
,
Deplus
R
, et al
.
The Polycomb group protein EZH2 directly controls DNA methylation [published correction appears in Nature. 2007;446(7137):824]
.
Nature
.
2006
;
439
(
7078
):
871
-
874
.
88.
Vaz
M
,
Hwang
SY
,
Kagiampakis
I
, et al
.
Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations
.
Cancer Cell
.
2017
;
32
(
3
):
360
-
376
.
89.
Azuara
V
,
Perry
P
,
Sauer
S
, et al
.
Chromatin signatures of pluripotent cell lines
.
Nat Cell Biol
.
2006
;
8
(
5
):
532
-
538
.
90.
Bernstein
BE
,
Mikkelsen
TS
,
Xie
X
, et al
.
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
.
Cell
.
2006
;
125
(
2
):
315
-
326
.
91.
Huntly
BJ
,
Shigematsu
H
,
Deguchi
K
, et al
.
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
.
Cancer Cell
.
2004
;
6
(
6
):
587
-
596
.
92.
Pellicano
F
,
Park
L
,
Hopcroft
LEM
, et al
.
hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival
.
Blood
.
2018
;
131
(
14
):
1532
-
1544
.
93.
Maifrede
S
,
Magimaidas
A
,
Sha
X
,
Mukherjee
K
,
Liebermann
DA
,
Hoffman
B
.
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia
.
Oncotarget
.
2017
;
8
(
41
):
69281
-
69294
.
94.
Maxwell
MA
,
Muscat
GE
.
The NR4A subgroup: immediate early response genes with pleiotropic physiological roles
.
Nucl Recept Signal
.
2006
;
4
(
1
):
e002
.
95.
Lammi
J
,
Huppunen
J
,
Aarnisalo
P
.
Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts
.
Mol Endocrinol
.
2004
;
18
(
6
):
1546
-
1557
.
96.
McWeeney
SK
,
Pemberton
LC
,
Loriaux
MM
, et al
.
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
.
Blood
.
2010
;
115
(
2
):
315
-
325
.
97.
Yong
AS
,
Szydlo
RM
,
Goldman
JM
,
Apperley
JF
,
Melo
JV
.
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
.
Blood
.
2006
;
107
(
1
):
205
-
212
.
98.
Wang
GG
,
Konze
KD
,
Tao
J
.
Polycomb genes, miRNA, and their deregulation in B-cell malignancies
.
Blood
.
2015
;
125
(
8
):
1217
-
1225
.
99.
Amabile
G
,
Di Ruscio
A
,
Müller
F
, et al
.
Dissecting the role of aberrant DNA methylation in human leukaemia
.
Nat Commun
.
2015
;
6
(
1
):
7091
.
100.
Sharma
S
,
Kelly
TK
,
Jones
PA
.
Epigenetics in cancer
.
Carcinogenesis
.
2010
;
31
(
1
):
27
-
36
.
101.
Sirin
O
,
Lukov
GL
,
Mao
R
,
Conneely
OM
,
Goodell
MA
.
The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells
.
Nat Cell Biol
.
2010
;
12
(
12
):
1213
-
1219
.
102.
Mullican
SE
,
Zhang
S
,
Konopleva
M
, et al
.
Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia
.
Nat Med
.
2007
;
13
(
6
):
730
-
735
.
103.
Ramirez-Herrick
AM
,
Mullican
SE
,
Sheehan
AM
,
Conneely
OM
.
Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice
.
Blood
.
2011
;
117
(
9
):
2681
-
2690
.
104.
Freire
PR
,
Conneely
OM
.
NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling
.
Blood
.
2018
;
131
(
10
):
1081
-
1093
.
105.
Infante
JR
,
Bedard
PL
,
Shapiro
G
, et al
.
Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein
.
J Clin Oncol
.
2017
;
35
(
15_suppl
):
2574
.
This content is only available as a PDF.
You do not currently have access to this content.